SEC Filing Summary

This filing details transactions related to Crinetics Pharmaceuticals, Inc. (CRNX) on September 1, 2026, as part of a merger with Vertex Pharmaceuticals Incorporated. Director Vivaldi Coelho Rogerio reported the disposition of 13,300 shares of Common Stock at $85.00 per share, followed by the disposition of the remaining 5,925 shares at the same price. Additionally, various stock options were canceled and converted into cash payments, with the reported prices reflecting the difference between the merger consideration and the strike price. These transactions were part of the merger agreement where Crinetics Pharmaceuticals, Inc. was acquired by Vertex Pharmaceuticals Incorporated.